PE20091678A1 - Agonistas de los receptores muscarinicos, composiciones, metodos de tratamiento en que se emplean y sus procesos de preparacion-176 - Google Patents

Agonistas de los receptores muscarinicos, composiciones, metodos de tratamiento en que se emplean y sus procesos de preparacion-176

Info

Publication number
PE20091678A1
PE20091678A1 PE2009000326A PE2009000326A PE20091678A1 PE 20091678 A1 PE20091678 A1 PE 20091678A1 PE 2009000326 A PE2009000326 A PE 2009000326A PE 2009000326 A PE2009000326 A PE 2009000326A PE 20091678 A1 PE20091678 A1 PE 20091678A1
Authority
PE
Peru
Prior art keywords
alkyl
treatment
agonists
compositions
methods
Prior art date
Application number
PE2009000326A
Other languages
English (en)
Inventor
Jin Shujuan
Miroslaw Jerzy Tomaszewski
Vijay Aratnam Santhakumar
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41013663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091678(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20091678A1 publication Critical patent/PE20091678A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

REFERIDO A UN COMPUESTO DE FORMULA (I), DONDE X ES DE PREFERENCIA CH2, NH, -O-, -S-; R1 ES H, HALO, -CN, ENTRE OTROS; R2 ES -C(=O)ORa Y -C(=O)NRcRd; R3 ES ALQUILO C1-C6, HALOALQUILO C1-C6; R4 Y R5 SON CADA UNO HALO, ALQUILO C1-C6, HALOALQUILO C1-C6, ENTRE OTROS; Ra ES ALQUILO C1-C7, HALOALQUILO C1-C7, ALQUENILO C2-C6, ENTRE OTROS; Rc Y Rd SON CADA UNO H, ALQUILO C1-C7, ALQUENILO C2-C6, ENTRE OTROS; n ES 0-4; m ES 0-8; p ES 0-6. SON COMPUESTOS SELECCIONADOS: 3-METIL-3-(4-(2-OXO-2,3-DIHIDRO-1H-BENZO[D]IMIDAZOL-1-IL)PIPERIDIN-1-IL)PIRROLIDINA-1-CARBOXILATO DE ETILO; 3-(4-(4-TERC-BUTIL-6-METIL-2-OXOINDOLIN-1-IL)PIPERIDIN-1-IL)-3-METILPIRROLIDINA-1-CARBOXILATO DE METILO; 3-(4-(6'-FLUORO-2'-OXOSPIRO[CICLOPROPANO-1,3'-INDOLINA]-1'-IL)PIPERIDIN-1-IL)-3-METILPIRROLIDINA-1-CARBOXILATO DE ETILO; ENTRE OTROS. TAMBIEN SE REFIERE A UN METODO DE PREPARACION. DICHO COMPUESTO ES AGONISTA DE LOS RECEPTORES MUSCARINICOS, SIENDO UTIL EN EL TRATAMIENTO DEL DOLOR
PE2009000326A 2008-03-03 2009-03-03 Agonistas de los receptores muscarinicos, composiciones, metodos de tratamiento en que se emplean y sus procesos de preparacion-176 PE20091678A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3308208P 2008-03-03 2008-03-03

Publications (1)

Publication Number Publication Date
PE20091678A1 true PE20091678A1 (es) 2009-12-04

Family

ID=41013663

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000326A PE20091678A1 (es) 2008-03-03 2009-03-03 Agonistas de los receptores muscarinicos, composiciones, metodos de tratamiento en que se emplean y sus procesos de preparacion-176

Country Status (15)

Country Link
US (1) US20090221642A1 (es)
EP (1) EP2262795A4 (es)
JP (1) JP2011513394A (es)
KR (1) KR20100131469A (es)
CN (1) CN102015688A (es)
AR (1) AR070744A1 (es)
AU (1) AU2009220270A1 (es)
BR (1) BRPI0908563A2 (es)
CA (1) CA2717478A1 (es)
CL (1) CL2009000491A1 (es)
MX (1) MX2010009756A (es)
PE (1) PE20091678A1 (es)
RU (1) RU2010136721A (es)
TW (1) TW200940056A (es)
WO (1) WO2009110844A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815405A (en) * 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
TW200813018A (en) * 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
US20110295013A1 (en) * 2009-02-03 2011-12-01 Hiroshi Iwamura Process for preparing 1-(4-piperidinyl)benzimidazolone derivatives
US8362270B2 (en) * 2010-05-11 2013-01-29 Xerox Corporation Self-assembled nanostructures
TW201211028A (en) * 2010-08-10 2012-03-16 Dainippon Sumitomo Pharma Co Fused ring pyrrolidine derivatives
JP2015083543A (ja) * 2012-02-14 2015-04-30 大日本住友製薬株式会社 新規縮環ピロリジン誘導体
CA2873672A1 (en) 2012-05-21 2013-11-28 Novartis Ag Novel ring-substituted n-pyridinyl amides as kinase inhibitors
RU2666532C2 (ru) * 2013-06-19 2018-09-11 Ф. Хоффманн-Ля Рош Аг Производные индолин-2-она или пирролопиридин/пиримидин-2-она

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1221443B1 (en) * 1999-10-13 2004-09-01 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
JP2005532361A (ja) * 2002-06-17 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症の治療用の眼科用組成物
ES2391107T3 (es) * 2005-09-30 2012-11-21 Glaxo Group Limited Compuestos que tienen actividad en el receptor M1 y sus usos en medicina
TW200815405A (en) * 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
TW200813018A (en) * 2006-06-09 2008-03-16 Astrazeneca Ab Novel compounds
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators

Also Published As

Publication number Publication date
BRPI0908563A2 (pt) 2017-05-23
CN102015688A (zh) 2011-04-13
AU2009220270A1 (en) 2009-09-11
JP2011513394A (ja) 2011-04-28
CL2009000491A1 (es) 2010-05-14
EP2262795A4 (en) 2012-03-07
WO2009110844A1 (en) 2009-09-11
CA2717478A1 (en) 2009-09-11
MX2010009756A (es) 2010-10-15
EP2262795A1 (en) 2010-12-22
US20090221642A1 (en) 2009-09-03
RU2010136721A (ru) 2012-04-10
TW200940056A (en) 2009-10-01
AR070744A1 (es) 2010-04-28
KR20100131469A (ko) 2010-12-15

Similar Documents

Publication Publication Date Title
PE20091678A1 (es) Agonistas de los receptores muscarinicos, composiciones, metodos de tratamiento en que se emplean y sus procesos de preparacion-176
AR064355A1 (es) Herbicidas derivados de isoxazol
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PE20110397A1 (es) Compuestos que modulan selectivamente el receptor cb2
PE20081659A1 (es) Agonistas de gpcr
AR055635A1 (es) Uso de sulfonanilidas como herbicidas
PE20020510A1 (es) DERIVADOS DE AZEPILO [4,5b] INDOLINA SUSTITUIDOS COMO LIGANDOS DE LOS RECEPTORES DE SEROTONINA (5-HT)
PE20081783A1 (es) Nuevas 2-aminooxazolinas como ligandos de taar1
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
PE20081504A1 (es) Compuestos de biciclocarboxiamida sustituidos
PE20080889A1 (es) Aminometil-4-imidazoles
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
EA200300777A1 (ru) N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов для fsad
PE20090896A1 (es) Derivados de amidas como ligandos de los receptores taar1
PE20081851A1 (es) Derivados de espiropiperidina-glicinamida
PE20100718A1 (es) Derivados triciclicos de 1, 4-dihidropiridina [b, e]-condensados como inhibidores de aurora quinasas
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
CO6260005A2 (es) Composiciones agricolas que comprenden dialquil amidas como solvente
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
AR060812A1 (es) Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn
ES2294313T3 (es) Derivados de piridina como moduladores del receptor cb2.
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
CO6331307A2 (es) Derivados de imidazo[1,2alfa]piridin-2-carboxamidas su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FD Application declared void or lapsed